Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
Company on track to submit Investigational New Drug application for CPI-818 in early 2019 BURLINGAME, Calif., Jan. 10, 2019 (GLOBE […]